-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Barriers to Access to New Lung Cancer Drugs in Latin America
By Pedro N. Aguiar Jr., MD, MSc, andGilberto L. Lopes Jr., MD, MBA Posted: April 2018 After often-painful but effective and still incomplete economic reforms, more rational government spending, and the increased trade brought about by globalization, Latin America has lifted itself out of the misery of its recent past and has started to tackle…
-
Q&A with the New IASLC President
Posted: February 2018 Giorgio Vittorio Scagliotti, MD, Professor of Oncology at University of Torino and Head of the Department of Oncology and Chief of the Division of Medical Oncology at the San Luigi Hospital in Torino, Italy, earned his medical degree and completed his postgraduate training in respiratory medicine, internal medicine, and medical oncology at…
-
Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC
By Hossein Borghaei, MS, DO Posted: February 2018 The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who are treatment naive who do not have a driver mutation and who have a high PD-L1 expression (≥50% tumor proportion score), frontline pembrolizumab is the accepted standard…
-
Laurie E. Gaspar, MD, MBA
Posted: February 2018 Laurie E. Gaspar, MD, MBA, has been elected as the 2019- 2020 Treasurer of ASCO. Dr. Gaspar is Professor Emeritus in the Department of Radiation Oncology at the University of Colorado, with continued clinical interest in the management of brain tumors and lung cancer. She also conducts research in patient communication and…
-
Radon: A Modifiable Lung Cancer Risk Factor
By Douglas Arenberg, MD Posted: February 2018 There has been rapid change over the past decade in the field of lung cancer. Advances such as histology-specific treatments, targeted agents, immunotherapy, screening, and biomarkers dominate scientific journal pages, and rightfully so. Now more than ever, we lung cancer specialists have more tools to work with to…
-
European Union Position Statement on Lung Cancer CT Screening: The Next 18 Months
By John K. Field, PhD, and Matthijs Oudkerk, MD, PhD Lung cancer kills more Europeans than any other cancer. In 2014, 272,000 citizens of the twenty-eight countries in the European Union (EU) died from lung cancer, which is 20.1% of all cancer deaths.1 When implemented in the general population, lung cancer screening using CT saves…
-
The Upcoming Lung Cancer Neoadjuvant Meeting
(Photo: Gideon Blumenthal, MD, Nicole Drezner, MD, Mark G. Kris, MD) By Erik J. MacLaren, PhD Posted: February 2018 The development of immunotherapies and targeted therapies for use in lung cancers has provided less-toxic options for treating these malignancies. Researchers have begun investigating the possibility of using these newer drugs in the neoadjuvant setting, that is,…
-
Paolo Paoletti, MD
New IASLC Foundation Board Member Posted: February 2018 Dr. Paoletti is the Chairman of the Board for Genmab, PsiOxus Therapeutics (Chairman of the Board), FORMA Therapeutics, and Nucana Biomed. He was formerly the first appointed president of GSK Oncology, where he was responsible for championing an organization of more than 2,000 professionals around the world…
-
Targeted Therapies Meeting Focuses on Upcoming Research Advances in Lung Cancer
By Chairs Suresh Ramalingam, MD, Paul Bunn, MD, PhD, Leora Horn, MD, MSc, and Roy Herbst, MD, PhD Posted: February 2018 Lung cancer research has reached an exciting point with the availability of a plethora of therapeutic strategies that have resulted in improved outcomes for patients. Recent advances include novel targeted therapies based on genomic…
-
Howard A. “Skip” Burris III, MD
Posted: February 2018 Howard A. “Skip” Burris III, MD, has been elected to serve as the 2019-2020 President of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2019. Dr. Burris is president of clinical operations and chief medical officer for Sarah Cannon, the Cancer Institute of HCA Healthcare. He is…